ACST - Rasio utang marang kapitalisasi buku acastipharma.com

Acasti Pharma (ACST) develops unique therapies for orphan nervous system pathologies, backed by FDA exclusivity protections. The debt-to-equity ratio demonstrates financial stability, with the metric reaching 0.00. Physicians value Acasti Pharma for its pursuit of solutions to complex cardio-metabolic issues, while the company achieves cost optimization by outsourcing trials to external CRO networks.

Investors use this indicator to assess long-term financial stability and bankruptcy risks. The metric is calculated as the ratio of total debt to total equity, determining the business's degree of reliance on borrowings. The current value of 0.00 on the leverage chart—debt to book capitalization—reflects the current balance of liabilities. A decrease in this ratio confirms the solvency of Acasti Pharma (ACST). This is critically important for financing the development of innovative mucosal drug delivery systems.